Time trends in incidence of peptic ulcer bleeding and associated risk factors in Norway 1985-2008 [0.03%]
挪威1985-2008年消化性溃疡出血发病率及其危险因素的时间变化趋势
Kåre E Bakkevold
Kåre E Bakkevold
Objective: The aim of this study was to examine time trends in the incidence of peptic ulcer bleeding and risk factors in a defined geographical area in Norway. ...
Intestinal fermentation in patients with self-reported food hypersensitivity: painful, but protective? [0.03%]
自认为对食物过敏的患者肠道发酵：痛苦，但具有保护作用？
Jørgen Valeur,Mette Helvik Morken,Elisabeth Norin et al.
Jørgen Valeur et al.
Purpose: Enterometabolic disturbances may cause meal-related symptoms. We performed a functional evaluation of the intestinal microflora in patients with unexplained, self-reported food hypersensitivity by measuring fecal...
Kalyan Ray Parashette,Raghavendra Charan Makam,Carmen Cuffari
Kalyan Ray Parashette
Anti-tumor necrosis factor alpha (TNF-α) therapy has re-defined our treatment paradigms in managing patients with Crohn's disease (CD) and ulcerative colitis. Although the ACCENT studies showed proven efficacy in the induction and maintena...
Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation [0.03%]
普鲁卡必利的作用机制及其治疗慢性便秘的效果评估：一项系统综述和 meta 分析
Banny S Wong,Noriaki Manabe,Michael Camilleri
Banny S Wong
Constipation affects up to a quarter of the population in developed countries and is associated with poor quality of life and significant economic burden. Many patients with chronic constipation are dissatisfied with current therapy due to ...
Imatinib as the first and only treatment in Europe for adult patients at significant risk of relapse following gastrointestinal stromal tumor removal [0.03%]
伊马替尼作为欧盟成人胃肠间质瘤切除术后复发高风险患者的首选和唯一治疗药物
F Duffaud,S Salas,T Huyn et al.
F Duffaud et al.
Mutations of the KIT gene are the molecular hallmark of most gastrointestinal stromal tumors (GISTs). GIST has become a model for targeted treatment of solid tumors, imatinib becoming the standard first-line treatment of these tumors in the...
Hugh James Freeman
Hugh James Freeman
Different hepatic and biliary tract disorders may occur with celiac disease. Some have been hypothesized to share genetic or immunopathogenetic factors, such as primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepat...
Inflammatory bowel diseases and the general practitioner's role in a region of Central Italy [0.03%]
意大利中部地区的炎症性肠病与全科医生的作用
Paolo Sossai,Fabio Filippetti,Ali Ahmad Muselmani et al.
Paolo Sossai et al.
Background: Inflammatory bowel diseases (IBD) are a serious burden for both patients and health care providers because of the young age at which they occur and their chronic course. ...
Delayed-release oral suspension of omeprazole for the treatment of erosive esophagitis and gastroesophageal reflux disease in pediatric patients: a review [0.03%]
奥美拉唑缓释口服悬液治疗儿童食管炎和胃食管反流病的疗效评价
Alice Monzani,Giuseppina Oderda
Alice Monzani
Omeprazole is a proton-pump inhibitor indicated for gastroesophageal reflux disease and erosive esophagitis treatment in children. The aim of this review was to evaluate the efficacy of delayed-release oral suspension of omeprazole in child...
An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease [0.03%]
潘妥拉唑治疗胃食管反流病的最新研究进展
Sony Mathews,Ashley Reid,Chenlu Tian et al.
Sony Mathews et al.
Gastroesophageal reflux disease (GERD) is a chronic, recurrent disease that affects nearly 19 million people in the US. The mainstay of therapy for GERD is acid suppression. Proton pump inhibitors (PPIs) are the most effective medication fo...
Stem cell therapeutics: potential in the treatment of inflammatory bowel disease [0.03%]
干细胞治疗在炎症性肠病治疗中的潜力
Es Swenson,Nd Theise
Es Swenson
Stem cell therapies may be valuable in treatment of inflammatory bowel disease (IBD). Here we focus on two very different types of stem cells - hematopoietic stem cells and mesenchymal stem cells. Myeloablation and hematopoietic stem cell t...